Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis - Galli, Mattia; Occhipinti, Giovanni; Benenati, Stefano; Laborante, Renzo; Ortega-Paz, Luis; Franchi, Francesco; D'Amario, Domenico; Nerla, Roberto; Castriota, Fausto; Frati, Giacomo; Biondi-Zoccai, Giuseppe; Sciarretta, Sebastiano; et al. (European heart journal. Cardiovascular pharmacotherapy, 2024)
Keywords: Allelomorphism; Angioplasty; Cardiology; Cilostazol - administration & dosage; Cilostazol - adverse effects; Cilostazol - pharmacokinetics; Clopidogrel; Clopidogrel - administration & dosage; Clopidogrel - adverse effects; Clopidogrel - pharmacokinetics; Comparative analysis; Coronary Artery Disease - genetics; Cytochrome; Cytochrome P-450 CYP2C19 - genetics; Drug dosages; Heterozygote; Humans; Loss of Function Mutation; Metabolites; Percutaneous Coronary Intervention - adverse effects; Pharmacodynamics; Pharmacogenomic Variants; Phenotype; Physiological aspects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - pharmacokinetics; Prasugrel Hydrochloride - administration & dosage; Prasugrel Hydrochloride - adverse effects; Prasugrel Hydrochloride - pharmacokinetics; Randomized Controlled Trials as Topic; Risk Factors; Ticagrelor; Ticagrelor - administration & dosage; Ticagrelor - adverse effects; Ticagrelor - pharmacokinetics; Transluminal angioplasty; Treatment Outcome; Antiplatelet therapy; Prasugrel; Guided-therapy; Clopidogrel resistance; Genotype; CYP2C19; Ticagrelor